Centre Issues Advisory on Handling Mucormycosis Infection Among Some COVID-19 Patients

Centre Issues Advisory on Handling Mucormycosis Infection Among Some COVID-19 Patients

The Union Health Ministry along with the Indian Council of Medical Research (ICMR) has posted an advisory on the management of a fungal infection known as ‘mucormycosis’ that is being spotted among a section of the patients that have recovered from the coronavirus

The advisory explains that mucormycosis (also known as ‘black fungus’) primarily affects people who are taking medications that can reduce their body’s ability to effectively tackle environmental pathogens. This particular infection could be deadly if not treated, the advisory said.

ReadCOVID-19 Cases In Home Quarantine Down By 16%

The ICMR went on to say that major risk factors for this particular disease include malignancy and voriconazole therapy, uncontrolled diabetes mellitus, immunosuppression by steroids, and long-term ICU stay. 

“Mucormycosis, if uncared for, may turn fatal. Sinuses or lungs of such individuals get affected after fungal spores are inhaled from the air,” the Centre said. 

Also readState To Form A Pediatric Task Force Keeping Third COVID-19 Wave In Mind

Some of the other basic symptoms of mucormycosis include fever, headache, shortness of breath, pain and redness around the eyes and nose, bloody vomit, and an altered mental status. 

Further, for COVID-19 patients who are immuno-suppressed and have diabetes, symptoms for mucormycosis could be sinusitis, blackish discolouration on the bridge of the nose or palate, facial pain or numbness on one side, toothache, skin lesions, double or blurred vision with pain, chest pain, thrombosis, and deteriorating respiratory symptoms.

ReadAll You Need To Know About DRDO's New Oral COVID-19 Drug '2-DG'

Read this story in हिंदी
MumbaiLive would like to send you latest news updates